Medical technology company Becton, Dickinson and Company (NYSE: BDX) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 8.9% year on year to $5.51 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $21.85 billion at the midpoint. Its non-GAAP profit of $3.68 per share was 8.2% above analysts’ consensus estimates.

Is now the time to buy BDX? Find out in our full research report (it’s free).

StockStory’s Take

BD’s third quarter was marked by a strong positive market reaction, reflecting investor confidence in the company’s margin expansion and execution on commercial initiatives. Management credited the improvement to gains in gross and operating margins, driven by the BD Excellence operating system, and highlighted sequential revenue growth across multiple product lines. CEO Thomas Polen emphasized the impact of new product launches and ongoing investments in sales and marketing as pivotal to the quarter’s performance, noting, “The combination of these actions has already begun delivering results, as you saw play out in a number of key areas.”

Looking forward, BD’s updated guidance is anchored by its strategy to accelerate organic growth through continued investment in innovation and commercial resources. Management highlighted the upcoming separation of its Biosciences and Diagnostics business and ongoing efforts to offset tariff impacts as critical to the company’s future trajectory. CFO Christopher DelOrefice stated that, “We want to keep investing in both innovation and commercial execution,” while CEO Polen pointed to a robust pipeline of product launches and operational efficiencies that are expected to drive momentum into 2026.

Key Insights from Management’s Remarks

Management attributed quarterly performance to growth in biologics, expansion in interventional products, and margin gains from operational improvements.

• Biologics and Pharm Systems Growth: Strong demand for biologics fueled continued double-digit growth in the Pharm Systems division, with CEO Thomas Polen noting the company is “exceptionally well positioned to capitalize on the wave of new molecules coming to market.”
• Urology and Interventional Momentum: The urology and critical care (UCC) segment sustained double-digit growth, supported by the success of PureWick products and expansion into home care and upcoming mobile device launches.
• Innovation Pipeline Delivery: Management highlighted rapid progress in its innovation cycle, including the launch of FACSDiscover A8 for cell imaging, FDA submission of an at-home HPV self-collection kit, and the initial clinical use of the Libertas Wearable Injector for self-injection of complex drugs.
• Operational Efficiency via BD Excellence: The BD Excellence lean operating system enabled significant productivity gains, waste reduction, and improved on-time delivery, contributing to higher margins and increased production capacity.
• Strategic Portfolio Actions: BD announced a definitive agreement to separate its Biosciences and Diagnostics business through a Reverse Morris Trust with Waters, aiming to create a streamlined, pure-play medical technology company and unlock shareholder value.

Drivers of Future Performance

BD expects continued growth to be led by product innovation, commercial expansion, and ongoing investments in operational efficiency, while monitoring macroeconomic and tariff-related headwinds.

• Product Launches and Expansion: Management is prioritizing the rollout of new medical devices such as the Pyxis Pro and mobile PureWick, alongside expanding biosimilar agreements, to drive revenue and deepen market penetration.
• Portfolio Realignment and Capital Allocation: The planned separation of the Biosciences and Diagnostics business is expected to create a focused medical technology company, with proceeds directed toward share buybacks and debt reduction, supporting future earnings growth.
• Tariff Mitigation and Cost Management: The company is actively managing tariff impacts through sourcing changes and operational adjustments, with CFO Christopher DelOrefice noting ongoing efforts to “whittle down” tariff costs, though these remain a notable risk to margin in 2026.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will monitor (1) the execution and closing timeline of the Waters transaction and resulting changes to BD’s business mix, (2) the pace of adoption for new launches like Pyxis Pro and the at-home HPV test, and (3) the impact of ongoing tariff mitigation efforts on margins. Progress in these areas will be crucial indicators of BD’s ability to sustain growth and navigate external headwinds.

BD currently trades at $192.82, up from $172.40 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

Stocks That Trumped Tariffs

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.